Disruption of the TRAC gene, which encodes the alpha chain of the TCR, has been identified as an effective method to prevent GVHD without compromising the anti-tumour efficacy of CAR-T cells (178, 179)This technique has been applied in clinical trials, as in the case of the UCART19 product, a product that involves the use of transcription activator-like nucleases (TALEN) to simultaneously knock out TRAC and CD52 genes, observing 64% knockout in CAR-T cells, without causing severe GVHD in treated patients (180. Here, CD52 is linked to neoplasm.